Quoc Hoai Tran
Research Subjects
Quoc Hoai Tran has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Bassim Jebeili1 shared publication
- Bhadran Bose
Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia
1 shared publication - Hannah Ainsworth
Gosford District Hospital, Gosford, NSW, Australia
1 shared publication - Jonathan Kam
Nepean Urology Research Group Kingswood New South Wales Australia
1 shared publication - Kamal Sud
Sydney Medical School, Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
1 shared publication - Mark Louie-Johnsun
Department of Urology, Geelong Hospital, Geelong, Victoria, Australia
1 shared publication
Latest Publications
- 1 March 2019
- Published by Elsevier in Journal of Surgical Education
- Vol. 76 (2) , 440-445
Portable Video Media Versus Standard Verbal Communication in Surgical Teaching: A Prospective, Multicenter, and Randomized Controlled Crossover Trial
- 1 March 2019
- Published by Elsevier in Journal of Surgical Education
- Vol. 76 (2) , 440-445
Portable Video Media Versus Standard Verbal Communication in Surgical Teaching: A Prospective, Multicenter, and Randomized Controlled Crossover Trial
- Open Access
- 29 August 2018
- Published by IntechOpen
Anticoagulation for Atrial Fibrillation in Patients with End- Stage Kidney Disease
Atrial fibrillation (AF) is common in patients with kidney disease, with prevalence several times greater than in the general population. Anticoagulation agents are used to prevent thromboembolic events as a consequence of AF. Several randomized trials have established the efficacy of antithrombotic drugs for preventing stroke in patients with AF, with both antiplatelet agents and oral anticoagulants showing benefit. End-stage kidney disease (ESKD) patients have known platelet defects/dysfunction and also receive heparin during their dialysis treatment, which contributes to their overall coagulopathy. Warfarin being vitamin-K antagonist can augment calciphylaxis in patients with ESKD. Taken together, formal anticoagulation use in patients with ESKD may confer additional risk that is not appreciated in patients without kidney disease. In particular, patients on new oral anticoagulants show excess morbidity and mortality from bleeding when compared to warfarin.
- 29 August 2018
- Published by IntechOpen
Open AccessAnticoagulation for Atrial Fibrillation in Patients with End- Stage Kidney Disease
Atrial fibrillation (AF) is common in patients with kidney disease, with prevalence several times greater than in the general population. Anticoagulation agents are used to prevent thromboembolic events as a consequence of AF. Several randomized trials have established the efficacy of antithrombotic drugs for preventing stroke in patients with AF, with both antiplatelet agents and oral anticoagulants showing benefit. End-stage kidney disease (ESKD) patients have known platelet defects/dysfunction and also receive heparin during their dialysis treatment, which contributes to their overall coagulopathy. Warfarin being vitamin-K antagonist can augment calciphylaxis in patients with ESKD. Taken together, formal anticoagulation use in patients with ESKD may confer additional risk that is not appreciated in patients without kidney disease. In particular, patients on new oral anticoagulants show excess morbidity and mortality from bleeding when compared to warfarin.